278 related articles for article (PubMed ID: 24069383)
1. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
[TBL] [Abstract][Full Text] [Related]
2. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
3. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
[TBL] [Abstract][Full Text] [Related]
4. Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.
Hagberg Thulin M; Jennbacken K; Damber JE; Welén K
Clin Exp Metastasis; 2014 Mar; 31(3):269-83. PubMed ID: 24292404
[TBL] [Abstract][Full Text] [Related]
5. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis.
Hagberg Thulin M; Nilsson ME; Thulin P; Céraline J; Ohlsson C; Damber JE; Welén K
Mol Cell Endocrinol; 2016 Feb; 422():182-191. PubMed ID: 26586211
[TBL] [Abstract][Full Text] [Related]
6. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions.
Akech J; Wixted JJ; Bedard K; van der Deen M; Hussain S; Guise TA; van Wijnen AJ; Stein JL; Languino LR; Altieri DC; Pratap J; Keller E; Stein GS; Lian JB
Oncogene; 2010 Feb; 29(6):811-21. PubMed ID: 19915614
[TBL] [Abstract][Full Text] [Related]
7. The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancer.
Al Nakouzi N; Bawa O; Le Pape A; Lerondel S; Gaudin C; Opolon P; Gonin P; Fizazi K; Chauchereau A
Neoplasia; 2012 May; 14(5):376-87. PubMed ID: 22745584
[TBL] [Abstract][Full Text] [Related]
8. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.
Li ZG; Mathew P; Yang J; Starbuck MW; Zurita AJ; Liu J; Sikes C; Multani AS; Efstathiou E; Lopez A; Wang J; Fanning TV; Prieto VG; Kundra V; Vazquez ES; Troncoso P; Raymond AK; Logothetis CJ; Lin SH; Maity S; Navone NM
J Clin Invest; 2008 Aug; 118(8):2697-710. PubMed ID: 18618013
[TBL] [Abstract][Full Text] [Related]
10. Canine prostate cancer cell line (Probasco) produces osteoblastic metastases in vivo.
Simmons JK; Dirksen WP; Hildreth BE; Dorr C; Williams C; Thomas R; Breen M; Toribio RE; Rosol TJ
Prostate; 2014 Sep; 74(13):1251-65. PubMed ID: 25043424
[TBL] [Abstract][Full Text] [Related]
11. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
[TBL] [Abstract][Full Text] [Related]
12. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
[TBL] [Abstract][Full Text] [Related]
14. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
16. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
[TBL] [Abstract][Full Text] [Related]
17. Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.
Joseph J; Shiozawa Y; Jung Y; Kim JK; Pedersen E; Mishra A; Zalucha JL; Wang J; Keller ET; Pienta KJ; Taichman RS
Mol Cancer Res; 2012 Mar; 10(3):282-92. PubMed ID: 22241219
[TBL] [Abstract][Full Text] [Related]
18. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.
Larson SR; Chin J; Zhang X; Brown LG; Coleman IM; Lakely B; Tenniswood M; Corey E; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2014 Feb; 31(2):247-56. PubMed ID: 24242705
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer.
Goya M; Ishii G; Miyamoto S; Hasebe T; Nagai K; Yonou H; Hatano T; Ogawa Y; Ochiai A
Prostate; 2006 Nov; 66(15):1573-84. PubMed ID: 16927388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]